Provided herein are compositions comprising anti-IGF-1R, anti-ErbB3 bispecific antibodies alone or in combination with other anti-cancer agents. Also provided are methods of treating a subject having cancer and methods for determining whether a patient with cancer is likely to respond to the compositions described herein.